Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 2/2014

01-02-2014 | Original Research

Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin

Authors: Jeffrey S. Stonebraker, Albert Farrugia, Benjamin Gathmann, Jordan S. Orange, ESID Registry Working Party

Published in: Journal of Clinical Immunology | Issue 2/2014

Login to get access

Abstract

Purpose

Estimating the underlying demand for immunoglobulin (Ig) is important to ensure that adequate provision is made for patients with primary immune deficiency (PID) in the context of the competing demands for Ig and to ensure optimal therapeutic regimens. The concept of latent therapeutic demand (LTD) was used to estimate evidence-based requirements and compared to the actual Ig consumption in different countries. The estimates were performed for common variable immunodeficiency (CVID) and X-linked Agammaglobulinaemia (XLA), the two most commonly studied PIDs using Ig.

Methods

The LTD model for CVID and XLA was derived using decision analysis methodology. Data for the epidemiology and treatment variables were obtained from peer-reviewed publications, clinical registries and publicly-available patient surveys. Incomplete data records from registries were excluded from analysis. The variables impacting LTD were ranked in order of sensitivity through a tornado diagram. The uncertainty surrounding the variables was modeled using probabilistic distributions and evaluated using Monte Carlo simulation.

Results

Treatment dosage and prevalence were determined to be the most sensitive variables driving demand. The average potential usage of Ig for the treatment of CVID and XLA was estimated at 72 g per 1,000 population, which is higher than the estimated Ig usage in CVID and XLA of 27–41 g per 1,000 population in the US.

Conclusion

The potential demand for treating CVID and XLA exceeds the currently observed usage of Ig in these disorders. Variable usage in different countries is due to varying prevalence and dosage practices. Under-reporting in patient registries represents a major obstacle to calculating the true prevalence of CVID and XLA. Modeling demand relies heavily upon accurate prevalence and practice estimates which reemphasize the importance of accurate registries and improved registry methods. As better data becomes available, revision of model variables provides opportunities to anticipate and prepare for evolving patient needs.
Literature
1.
Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;24 Suppl 1:S28–50.PubMedCrossRef
2.
3.
Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin N Am. 2008;28(4):737–64.CrossRef
4.
Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin N Am. 2008;28(4):765–78.CrossRef
5.
Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma—aspects of yield and virus safety. Biotechnol J. 2006;1(2):148–63.PubMedCrossRef
6.
7.
8.
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.PubMedCrossRef
9.
10.
11.
Farrugia A, Cassar J. Is self-sufficiency in haemotherapies a practical or necessary goal? Blood Transfus. 2012;13:1–12.
12.
Rossi F, Perry R, de Wit J, Evers T, Folléa G. How expanding voluntary non-remunerated blood donations would benefit patients, donors and healthcare systems? Vox Sang. 2011;101(2):176–7.PubMedCrossRef
13.
Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22.PubMedCentralPubMedCrossRef
14.
Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.PubMedCrossRef
15.
Goel V. Decision analysis: applications and limitations. The Health Services Research Group. CMAJ. 1992;147(4):413–7.PubMedCentralPubMed
16.
Stonebraker JS, Amand RE, Bauman MV, Nagle AJ, Larson PJ. Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. Haemophilia. 2004;10(1):18–26.PubMedCrossRef
17.
Stonebraker JS, Keefer DL. Modeling potential demand for supply-constrained drugs: a new hemophilia drug at Bayer Biological Products. Oper Res. 2009;57(1):19–31.CrossRef
18.
19.
Gathmann B, Grimbacher B, Beauté J, Dudoit Y, Mahlauoui N, Fischer A, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157 Suppl 1:3–11.PubMedCentralPubMedCrossRef
20.
Immune Deficiency Foundation: Primary immune deficiency diseases in America. Prepared by Schulman, Ronca and Bucuvalas, Inc., 1995.
21.
Immune Deficiency Foundation: Primary immune deficiency diseases in America: 2002. The second national survey of patients. Prepared by Schulman, Ronca and Bucuvalas, Inc., April 28, 2003
22.
Immune Deficiency Foundation: Treatment experiences and preferences of patients with primary immune deficiency diseases: First national survey. Prepared by Schulman, Ronca and Bucuvalas, Inc., June 20, 2003.
23.
Immune Deficiency Foundation: Primary immunodeficiency diseases in America: 2007. The third national survey of patients. Prepared by Abt SRBI, Inc., May 1, 2009.
24.
Immune Deficiency Foundation: Treatment experiences and preferences among patients with primary immunodeficiency diseases. National survey of patients: 2008. Prepared by Abt, SRBI, Inc., May 6, 2009.
25.
Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group—6. Med Decis Mak. 2012;32:722–32.CrossRef
26.
Keefer DL, Bodily SE. Three-point approximation for continuous random variables. Manag Sci. 1983;29:595–609.CrossRef
27.
Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372(9637):489–502.PubMedCrossRef
28.
Yong PFK, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin N Am. 2008;28(2):367–86.CrossRef
29.
30.
Abuzakouk M, Feighery C. Primary immunodeficiency disorders in the Republic of Ireland: first report of the National Registry in children and adults. J Clin Immunol. 2005;25(1):73–7.PubMedCrossRef
31.
Beauté J et al. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135:264–72.CrossRef
32.
Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27:497–502.PubMedCrossRef
33.
Edgar JDM, Buckland M, Guzman D, Conlon NP, Knerr V, et al. The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years’ activity 2008–2012. Clin Exp Immunol doi: 10.​1111/​cei.​12172.
34.
Gathmann B, Goldacker S, Klima M, et al. The German national registry for primary immunodeficiencies (PID). Clin Exp Immunol. 2013;173(2):372–80.PubMedCrossRef
35.
Golan H et al. The incidence of primary immunodeficiency syndromes in Israel. IMAJ. 2002;4(Suppl):868–71.PubMed
36.
Ishimura M et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31:968–76.PubMedCrossRef
37.
Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27(5):517–24.PubMedCrossRef
38.
Flori NM, Llambi JM, Boren TE, Borja SR, Casariego GF. Primary immunodeficiency syndrome in Spain: first report of the National Registry in children and adults. J Clin Immunol. 1997;17(4):333–9.CrossRef
39.
Modell V, Gee B, Lewis DB, Orange JS, Rolfman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.PubMedCrossRef
40.
Resnick ES, Bhatt P, Sidi P, Cunningham-Rundles C. Examining the use of ICD-9 Diagnosis Codes for primary immune deficiency diseases in New York State. J Clin Immunol. 2013;33:40–8.PubMedCentralPubMedCrossRef
41.
Ryser O, Morell A, Hitzig WH. Primary immunodeficiencies in Switzerland: first report of the National Registry in adults and children. J Clin Immunol. 1988;8(6):479–85.PubMedCrossRef
42.
Stray-Pedersen A, Abrahamsen TG, Frøland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol. 2000;20(6):477–85.PubMedCrossRef
43.
Furst DE. Serum immunoglobulins and risk of infection: how long can you go? Semin Arthritis Rheum. 2009;39(1):18–29.PubMedCrossRef
44.
McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2003–2006. National Health Statistics Reports: no. 10. Hyattsville: National Center for Health Statistics; 2008.
45.
Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People Statistics notes, no. 20. Hyattsville: National Center for Health Statistics; 2001.
46.
47.
Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255–63.PubMedCrossRef
48.
Hernandez-Trujillo HS, Chapel H, Lo Re 3rd V, Notarangelo LD, Gathmann B, Grimbacher B, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169(1):57–69.PubMedCentralPubMedCrossRef
49.
Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60.PubMedCrossRef
50.
51.
52.
Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893–908.PubMedCrossRef
53.
Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009–15.PubMedCrossRef
54.
Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1–S63.PubMedCrossRef
55.
Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1(8541):1075–7.PubMedCrossRef
56.
Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child. 1992;146(3):335–9.PubMed
57.
Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135(3):165–74.PubMedCrossRef
58.
Berger M. Incidence of infection is inversely related to steady-state (Trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol. 2011;31(5):924–6.PubMedCrossRef
59.
Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315–22.PubMedCrossRef
60.
Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol. 2005;115(2):412–7.PubMedCrossRef
61.
Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–86.PubMedCrossRef
62.
Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709–27.PubMedCentralPubMedCrossRef
63.
Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol. 2012;130(5):1197–1198e9.PubMedCrossRef
64.
Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol. 2012;130:S1–S24.PubMedCrossRef
65.
Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85.PubMedCrossRef
66.
Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol. 2011;127:1360–7.PubMedCentralPubMedCrossRef
67.
Stonebraker JS, Farrugia A, Gathmann B. A decision analysis model to estimate latent therapeutic demand for immunoglobulin therapy in primary immunodeficiencies. Proceedings of the 15th Meeting of the European Society of Immunodeficiencies—ESID (October 3–6, 2012, Florence, Italy). 2013;29–34.
68.
Schöndorf I. Resolving barriers to the treatment of primary immunodeficiencies. The Source. 2011;19–20.
Metadata
Title
Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin
Authors
Jeffrey S. Stonebraker
Albert Farrugia
Benjamin Gathmann
Jordan S. Orange
ESID Registry Working Party
Publication date
01-02-2014
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2014
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-013-9975-1

Other articles of this Issue 2/2014

Journal of Clinical Immunology 2/2014 Go to the issue

Brief Communication

Cartilage-Hair Hypoplasia: Follow-Up of Immunodeficiency in Two Patients

Astute Clinician Report

Autosomal Recessive Agammaglobulinemia: A Novel Non-sense Mutation in CD79a

Original Research

C3a, C5a Renal Expression and Their Receptors are Correlated to Severity of IgA Nephropathy

Original Research

Positive Correlation of STAT1 and miR-146a with Anemia in Patients with Systemic Lupus Erythematosus

Original Research

Caucasian Origin of Disease Associated HLA Haplotypes in Chinese Blood Donors with IgA Deficiency

Editorial

News from the CIS Executive Committee

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits